916 related articles for article (PubMed ID: 33400957)
1. Self-assembled mRNA vaccines.
Kim J; Eygeris Y; Gupta M; Sahay G
Adv Drug Deliv Rev; 2021 Mar; 170():83-112. PubMed ID: 33400957
[TBL] [Abstract][Full Text] [Related]
2. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
Milane L; Amiji M
Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
[TBL] [Abstract][Full Text] [Related]
3. Innovative Strategies to Enhance mRNA Vaccine Delivery and Effectiveness: Mechanisms and Future Outlook.
Verma A; Awasthi A
Curr Pharm Des; 2024; 30(14):1049-1059. PubMed ID: 38551046
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 mRNA vaccines.
Huang Q; Zeng J; Yan J
J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Review of mRNA Vaccines.
Gote V; Bolla PK; Kommineni N; Butreddy A; Nukala PK; Palakurthi SS; Khan W
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769023
[TBL] [Abstract][Full Text] [Related]
6. mRNA vaccine for cancer immunotherapy.
Miao L; Zhang Y; Huang L
Mol Cancer; 2021 Feb; 20(1):41. PubMed ID: 33632261
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and Challenges for mRNA Delivery Nanoplatforms.
Zhang Y; Hu Y; Tian H; Chen X
J Phys Chem Lett; 2022 Feb; 13(5):1314-1322. PubMed ID: 35107010
[TBL] [Abstract][Full Text] [Related]
8. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
9. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
Pascolo S
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
[TBL] [Abstract][Full Text] [Related]
11. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
[TBL] [Abstract][Full Text] [Related]
12. Research progress on the quality control of mRNA vaccines.
Hu C; Bai Y; Liu J; Wang Y; He Q; Zhang X; Cheng F; Xu M; Mao Q; Liang Z
Expert Rev Vaccines; 2024; 23(1):570-583. PubMed ID: 38733272
[TBL] [Abstract][Full Text] [Related]
13. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.
Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
Front Immunol; 2021; 12():679344. PubMed ID: 34305909
[TBL] [Abstract][Full Text] [Related]
14. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
15. How COVID unlocked the power of RNA vaccines.
Dolgin E
Nature; 2021 Jan; 589(7841):189-191. PubMed ID: 33437061
[No Abstract] [Full Text] [Related]
16. Non-viral COVID-19 vaccine delivery systems.
Park KS; Sun X; Aikins ME; Moon JJ
Adv Drug Deliv Rev; 2021 Feb; 169():137-151. PubMed ID: 33340620
[TBL] [Abstract][Full Text] [Related]
17. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.
Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K
Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884
[TBL] [Abstract][Full Text] [Related]
18. A network analysis of COVID-19 mRNA vaccine patents.
Gaviria M; Kilic B
Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
[No Abstract] [Full Text] [Related]
19. Delivery of synthetic mRNAs for tissue regeneration.
Steinle H; Weber J; Stoppelkamp S; Große-Berkenbusch K; Golombek S; Weber M; Canak-Ipek T; Trenz SM; Schlensak C; Avci-Adali M
Adv Drug Deliv Rev; 2021 Dec; 179():114007. PubMed ID: 34710530
[TBL] [Abstract][Full Text] [Related]
20. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
Jin L; Han Z; Zhao P; Sun K
Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
